Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1.
Psoriasis is a T-cell-mediated inflammatory skin disease which can be treated successfully with immunosuppressive drugs. Our purpose was to evaluate disease activity of psoriasis and the effect of immunosuppressive treatment by monitoring the soluble T-cell products sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. Twenty-two patients were treated orally with escalating dosages of cyclosporin A (n = 17)(3-5 mg/kg/day) or FK506 (n = 5)(0.05-0.15 mg/kg/day). The Psoriasis Area and Severity Index (PASI) was used to monitor clinical activity of psoriasis. Serum samples were analyzed by ELISA. sIL-2R levels showed the highest correlation with psoriasis disease activity (rs = 0.89; p < 0.05). The longitudinal part of this study showed that levels of sIL-2R and sCD27 decreased during immunosuppressive treatment but remained above normal even in patients successfully treated. Our data indicate that sIL-2R levels are well correlated with disease activity in patients with psoriasis. sIL-2R levels closely follow the decrease of disease activity during immunosuppressive treatment.
De Rie
M A
MA
Department of Dermatology, University of Amsterdam, The Netherlands.
Zonneveld
I M
IM
Witkamp
L
L
Van Lier
R A
RA
Out
T A
TA
Bos
J D
JD
D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood*; D015704:CD4 Antigens / Q000097:blood*; D016827:CD8 Antigens / Q000097:blood*; D016572:Cyclosporine / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood*; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011565:Psoriasis / Q000188:drug therapy / Q000473:pathology*; D015375:Receptors, Interleukin-2 / Q000097:blood*; D012720:Severity of Illness Index; D016559:Tacrolimus / Q000627:therapeutic use; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000097:blood*
D015415:Biomarkers; D015704:CD4 Antigens; D016827:CD8 Antigens; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; D018799:Intercellular Adhesion Molecule-1; D016572:Cyclosporine; D016559:Tacrolimus